These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 35288777)

  • 1. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
    Mazzeo S; Ingannato A; Giacomucci G; Manganelli A; Moschini V; Balestrini J; Cavaliere A; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Bagnoli S; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Eur J Neurol; 2024 Jan; 31(1):e16089. PubMed ID: 37797300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
    Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
    Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
    Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
    Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
    Lehmann S; Schraen-Maschke S; Vidal JS; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Delaby C; Hanon O;
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer's Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study.
    Shim Y
    Curr Alzheimer Res; 2023; 20(10):715-724. PubMed ID: 38299421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia.
    Giuffrè GM; Quaranta D; Costantini EM; Citro S; Martellacci N; De Ninno G; Vita MG; Guglielmi V; Rossini PM; Calabresi P; Marra C
    Neurobiol Dis; 2023 Oct; 186():106267. PubMed ID: 37652185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
    J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
    Götze K; Vrillon A; Bouaziz-Amar E; Mouton-Liger F; Hugon J; Martinet M; Dumurgier J; Cognat E; Zetterberg H; Blennow K; Hourrègue C; Paquet C; Lilamand M
    Neurobiol Dis; 2023 Jan; 176():105937. PubMed ID: 36462720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis.
    Fan Z; Liu X; Liu J; Chen C; Zhou M
    J Integr Neurosci; 2023 Jun; 22(4):85. PubMed ID: 37519166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment.
    Jing X; Wang L; Song M; Geng H; Li W; Huo Y; Huang A; Wang X; An C
    Sci Rep; 2024 Apr; 14(1):9072. PubMed ID: 38643230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Neurofilament Light Chain in Different Types of Dementia.
    Gu L; Shu H; Wang Y; Wang P
    Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.